This study aims to estimate the prevalence of antibodies against SARS-CoV-2 and help improve the prediction of infectious diseases and increase biosecurity in the Principality of Andorra
Keywords: COVID-19; Andorra; Screening; SARS-CoV-2; Epidemiology; Diagnostics
– 11% of Andorra’s population had antibodies against the virus during the first wave of the pandemic.
– By age group, prevalence was highest in adults over 90 years of age (15.2%), followed by adults aged 80-89 years (13.8%), adolescents aged 10-19 years (13.7%) and adults aged 50-59 years (13.6%).
– By population group, seroprevalence was higher in seasonal workers (13.3%)—those working in Andorra during ski season (October to May)—than in the general population (9.7%).
The study allowed us to identify infection hotspots and should contribute to the design of tailored interventions to prevent SARS-CoV-2 transmission in Andorra.Cristina Royo-Cebrecos, SAAS researcher and lead author of the study
Description of the Study:
- Title: Mass SARS-CoV-2 serological screening, a population-based study in the Principality of Andorra.
- Principal Investigator: Cristina Royo-Cebrecos.
- Co-Investigators: David Vilanova, Joel López, Vanesa Arroyo, Marc Pons, Guillem Francisco, Mireia G. Carrasco, Josep M. Piqué, Sergi Sanz, Carlota Dobaño and Alberto L. García-Basteiro.
- Coordinating Centres: The study is coordinated by the Servei Andorrà d’Atenció Sanitària (SAAS) and has the collaboration of the Institut de Salut Global de Barcelona (ISGlobal).
- Study Population: 91% of the population of the Principality of Andorra (70,624 inhabitants).
- Design: Two cross-sectional serological surveys were conducted throughout Andorra from 4 to 28 May 2020. Seroprevalence of antibodies against SARS-CoV-2 was estimated and the main socio-demographic factors associated with being seropositive were analysed.
- Methods: Serological surveys were performed using a rapid serological test (nCOV IgG/IgM) on a finger prick blood sample.
Objectives of the Study:
Principal Objective: To estimate SARS-CoV-2 seroprevalence throughout the Principality of Andorra by universal serological testing under a lockdown environment.
More about this Study:
Scientific Context: Andorra is a small country located in the Pyrenees attracting millions of visitors for tourism, mostly associated with skiing, and nature-related activities. As its neighbouring countries, Spain and France, it has been heavily affected by the COVID-19 pandemic.
Added Value: “This is the first seroprevalence study to assess the entire population of a country with universal serological testing and the largest of its kind worldwide,” explained ISGlobal researcher Alberto García-Basteiro, last author of the paper.
Servei Andorrà d’Atenció Sanitària (SAAS): It is a parapublic entity which, by delegation from the Ministry of Health, is responsible for providing most health care and coordinating all the activities carried out in Andorra in the field of public care.
Some of thefundamental objectives of the SAAS are to promote the most efficient use of all available resources to improve the level of health of the population of the Principality of Andorra; to fulfil the provision of health services, whether individual or collective, for all the population residing or travelling in the Principality of Andorra, in the form and conditions legally established for each case; to establish the appropriate organisation to facilitate health care which includes preventive, curative and rehabilitative aspects, in a coordinated manner between the different levels of care; to integrate all the health resources for public use in a single administrative and functional body and to guarantee the quality of health care and control of expenditure.
Other Studies about Serology:
Científicos franceses demuestran que la vacunación primaria con dos vacunas diferentes sería más eficaz que la vacunación con dos vacunas idénticas.
SAPRIS-SERO est une étude qui vise à estimer la séroprévalence de l’infection par le SRAS-CoV-2 dans les cohortes épidémiologiques Constances, E3-E4N, NutriNet-Santé et Elfe-Epipage2 en France.
Rejoignez l’étude COVonco et contribuez a comprendre mieux l’impact de la COVID-19 dans l’oncologie.
Le projet EpiCOV vise à fournir une cartographie globale et scientifiquement fiable du statut immunitaire de la population en France à travers des tests sérologiques et des questionnaires.
Early administration of convalescent plasma in people over 50 years of age with mild to moderate COVID-19 disease may slow disease progression and decrease the severity of symptoms.
Determining whether there is protection against reinfection is important for controlling healthcare workers implications during the pandemic due to their continous professional contact with COVID-19 patients
Identifying true markers of protective immunity will allow for the identification of individuals, in particular healthcare personnel working with COVID-19 patients and in other critical areas protected from re-infection.
The COVICAT study aims to evaluate the evolution of the incidence of SARS-CoV-2 coronavirus infection in the Catalan population over a 12-month period.
Convalescent plasma with anti-SARS-CoV-2 antibodies appears to be a very promising approach in the context of protracted COVID-19 symptoms in patients unable to mount a specific humoral response to SARS-CoV-2.
This cross-sectional study estimates SARS-CoV-2 IgG antibody seroprevalence in the community in England using self-administered LFIAs.